TREg Activation in the Treatment of the PELADE (Alopecia Areata)

TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2

In a prospective pilot study the investigators showed that low doses of IL2 could be beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated.

The objective of this study is to compare the long term efficacy of low doses of IL2 versus placebo in a multicenter prospective randomized double blind study.

Inclusion Criteria:

• Of more than 18 years old,
• Affiliated to the social security system,
• Clinical diagnosis of alopecia areata,
• 50 % of the surface of the scalp affected
• Last flaire started less than one year
• Alopecia areata resisting to at least 1 systematic treatment including phototherapy (UVB or PUVA), general corticosteroid therapy or methotrexate
• Signature of the informed consent

Exclusion Criteria:

• Pregnancy or refusal of contraception at the women old enough to procreate,
• Refusal of contraception at the men
• Local treatment (dermocorticoïdes, minoxidil) or systematism (oral corticosteroid therapy, méthotrexate or the other immunosuppresseur) since less than 2 less,
• Evolutionary autoimmune cancer or disease or in forgiveness
• Excessive grip(taking) of alcohol (upper to 3 glasses of wine a day or one pre-lunch drink a day)
• Seropositivity VHC, VHB, or HIV
• Patient presenting a severe renal and/or hepatic insufficiency,
• Presenting patient one zoned, the chicken pox, the herpes, the tuberculosis, an evolutionary infectious disease, a respiratory failure …
• Vulnerable person (nobody under guardianship minor(miner), adults, deprived of freedom)
• IC in the treatment(processing) by IL-2R
• Presenting a contraindication to ProleukinR